Franziska Meier-Stiegen

Franziska Meier-Stiegen

Auto-generated profile, based on publicly available information

Franziska Meier-Stiegen

Department of Obstetrics and Gynecology, University Hospital and Medical Faculty of the Heinrich-Heine University Duesseldorf, Düsseldorf, Deutschland

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 May 2014 in BioMed Research International
Verified
Journal Article
Open access
PDF file
NKNatalia Krawczyk
Natalia Krawczyk
FMFranziska Meier-Stiegen
Franziska Meier-Stiegen
MBMalgorzata Banys
Malgorzata Banys
HNHans Neubauer
Hans Neubauer
EREugen Ruckhaeberle
Eugen Ruckhaeberle
TFTanja Fehm
Tanja Fehm
Evaluation and characterization of circulating tumor cells (CTCs) have become a major focus of translational cancer research. Presence of CTCs predicts worse clinical outcome in early and metastatic breast cancer. Whether all cells from the primary tumor have potential to disseminate and form subsequent metastasis remains unclear. As part of the metastatic cascade, tumor cells lose their cell-to-cell adhesion and undergo epithelial-mesenchymal transition (EMT) in order to enter blood circulation. During EMT epithelial antigens are downregulated; thus, such tumor cells might elude classical epithelial marker-based detection. Several researchers postulated that some CTCs express stem cell-like phenotype; this might lead to chemoresistance and enhanced metastatic potential of such cells. In the present review, we discuss current data on EMT and stem cell markers in CTCs of breast cancer and their clinical significance.

1 January 2020 in The Journal of Molecular Diagnostics
Verified
Journal Article
Closed access
AFAndré Franken
André Franken
EHEllen Honisch
Ellen Honisch
FRFlorian Reinhardt
Florian Reinhardt
FMFranziska Meier-Stiegen
Franziska Meier-Stiegen
LYLiwen Yang
Liwen Yang
HNHans Neubauer
Hans Neubauer

20 May 2017 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
GGGerhard Gebauer
Gerhard Gebauer
Maggie Banys-PaluchowskiMaggie Banys-Paluchowski
Maggie Banys-Paluchowski
HNHans Neubauer
Hans Neubauer
NKNatalia Krawczyk
Natalia Krawczyk
AKAnna Kaczerowski
Anna Kaczerowski
TFTanja Fehm
Tanja Fehm
E17080 Background: Presence of circulating tumor cells (CTCs) in peripheral blood is associated with impaired clinical outcome in a variety of cancers. So far, limited data are available on the significance of CTCs in gynaecological malignancies. Aims of the present study were to evaluate the dynamics of CTCs in patients with ovarian, fallopian tube and peritoneal cancer during chemotherapy and to assess the clinical relevance of these changes. Methods: 38 patients with ovarian (n=31), fallopian tube (n=4) and peritoneal (n=3) cancer were included into the study. All patients received chemotherapy in the first-line setting (n=19) or tumor recurrence (n=19). CTC analysis was performed prior to systemic treatment, after three and six cycles of chemotherapy and analysed using CellSearch system (Veridex). A tumor cell was defined as EpCAM+, cytokeratin+, CD45-, and positive for the nuclear stain DAPI. CTC positivity was defined as detection of at least one CTC per 7.5 ml blood. Results: 11 out of 38 (29%) patients were CTC positive at baseline. Positivity rate was 20% in patients with first-line setting and 37% in those with tumor recurrence. 1of the 4 patients with fallopian tube cancer presented with CTCs in contrast to 1 out of 3 patients with peritoneal cancer and 10 out of 31 ovarian cancer patients. Presence of CTCs was not correlated with other prognostic factors, such as the FIGO stage, nodal status, or grading. CTC positivity declined to 8% after three cycles of cytotoxic therapy and no patient was CTC positive after 6 cycles of chemotherapy. 12 patients died during follow-up. Patients with CTCs at baseline had significantly shorter overall survival compared with CTC negative patients (p = 0.002; mean OS 5.8 [95%-CI 2.7-8.9] vs. 15.2 [10.5-19.8] months, median OS 3.0 [1.4-4.6] vs. not reached). In the subgroup of patients with primary cancer, CTC positivity was significantly associated with overall survival in the univariate analysis (p = 0.008). Conclusions: Hematogenous dissemination of single tumor cells is a common phenomenon in ovarian, fallopian tube and peritoneal cancer. Patients with CTCs in the peripheral blood at time of diagnosis are more likely to die than those who are CTC-negative at baseline.

10 June 2022 in Senologie - Zeitschrift für Mammadiagnostik und -therapie
Verified
Journal Article
Closed access
AFA. Franken
A. Franken
BJB. Jaeger
B. Jaeger
MRM. Rivandi
M. Rivandi
LYL. Yang
L. Yang
FMF. Meier-Stiegen
F. Meier-Stiegen
HNHans Neubauer
Hans Neubauer
Objective Targeted therapy has become the preferred approach to treat most cancers, including metastatic breast cancer. However, the predictive utility of the primary tumor is limited and obtaining serial biopsies of metastatic lesions is challenging. Therefore, using liquid biopsies, which can act as a dynamic diagnostic tool, is an appealing concept. Here, we performed a comparative mutation analysis of tissue biopsies and circulating tumor cells (CTCs) yielded from blood. Material & methods DNA from the most recent tissue biopsies available of 27 metastatic breast cancer patients was extracted. CTCs were enriched with the CellSearch system and were isolated by micromanipulation. Clinically relevant mutation in PIK3CA, ESR1, AKT1, and ERBB2 were identified by next generation sequencing. Results CTCs were detected in 18 samples and sequencing results were obtained for CTCs of 15 patients. CTC analysis failed in 3 cases due to DNA degradation and low quantity of the CTCs. Predictive mutations were detected in tissue of 10 patients. If CTC positive, similar mutations were found in CTCs in all cases. Moreover, in CTCs from 5 patients, further predictive mutations in PIK3CA, ESR1, or AKT1 were identified that could not be detected in tissue. Conclusion The analysis of CTCs offers the opportunity to detect predictive information that could not be gained from tissue biopsies but may be of clinical relevance. Therefore, liquid biopsies should be considered as a powerful tool that complements tissue analysis to optimize targeted therapy selection. Article published online: 21 June 2022 © 2022. Thieme. All rights reserved. Georg Thieme Verlag Rüdigerstraße 14, 70469 Stuttgart, Germany

5 September 2014 in Geburtshilfe und Frauenheilkunde
Verified
Journal Article
Closed access
RNR Neves
R Neves
KRK Raba
K Raba
OSO Schmidt
O Schmidt
EHE Honisch
E Honisch
FMF Meier-Stiegen
F Meier-Stiegen
NSN Stoecklein
N Stoecklein
Circulating tumour cells (CTCs) detected by CellSearchTM are important prognostic markers. To learn more about their biology and to use CTCs for clinical applications in sense of a liquid biopsy, we established and tested a workflow for purification of CTCs from CellSearchTM cartridges using a flow sorting approach and that allows their subsequent high-resolution genomic profiling. 34 CellSearchTM pre-processed breast cancer clinical samples were used for single CTCs sorting in a MoFlo sorter. Genome of single CTCs was amplified using an MseI adapter-linker-based PCR. Amplification products were analysed by high-resolution array-based comparative genomic hybridization (aCGH); gene specific real-time PCR based assay to confirm CyclinD1 locus amplification; and genomic sequencing to screen mutations in exon 20 of PIK3CA gene. A flow sorting protocol was appropriate to the analysis of almost 90% of the cartridges tested. The number of CTCs detected by flow cytometry correlated well with those detected by CellSearchTM. The genome of 72.9% of the sorted single CTCs could be amplified. In over 95% of the cells chromosomal aberrations typically observed in metastatic breast cancers were detected and results for CCND1 locus were validated by real-time PCR. Typical mutations in exon 20 of PIK3CA gene in cells isolated from two patients were detected. We present a workflow to isolate CTCs from clinical CellSearchTM samples enabling their subsequent genomic profiling using array CGH. Our data give an impression on the genomic makeup of CTCs from metastasized breast cancer patients at high-resolution and might significantly facilitate their further molecular characterization.